WealthyPlumber replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Thanks Lynnsa, I think LXX has a lot of advantage over others that want to produce edibles and having 19 patent applications adds value. The article worded this part very well
""the company’s DehydraTECH™ proprietary technology has been proven in both the laboratory and market to enhance the performance of beneficial compounds in ingestible products in what regards smell, taste, action duration and bio-availability and absorption. This allows for lower overall dosing and higher efficacy, a plus for cannabis suppliers and consumers alike.
The technology works with all ingested forms of cannabinoids, making Lexaria an enabler rather than a competitor, and allowing the company to develop partnerships with various biotech companies for cannabinoid research and development.""
lynnsa10 replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Whole Pot market is on fire or should I say smoking hot!! I am in no hurry to sell, I think LXX is still very cheap. This here article is probably helping today.
The rapid evolution of technology and its increasing application also serve as catalysts for M&A, as larger companies pursue opportunities that are positioned for current or near-term commercial availability. Such expertise and assets developed by smaller brands could potentially turn them into attractive targets for M&A activity. Lexaria Bioscience Corp. (OTCQB: LXRP) (LXRP Profile) is one such potential target due to its proprietary technology for improved taste, rapidity and delivery of bioactive compounds, including cannabinoids.
alexgreat replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
LXX at another new high
According to a 2016 report by Deloitte, the legal Canadian marijuana market could soon be worth $18 billion annually. As for volume, Deloitte forecast annual demand for the plant at about 1.32 million pounds per year.
Gambler replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
NetworkNewsWire Announces Publication Discussing Innovative New Delivery Platform for Cannabinoids, Tobacco and Medicine
New York, New York--(Newsfile Corp. - November 6, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a client of NNW that develops and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids.
The publication is titled, "Bioabsorption Breakthrough Shows Promise for Tobacco, Cannabinoids, Medication." It highlights a lipophilic technology developed to address the need for enhanced bio-absorption across multiple industries.
DearJohn replied the topic: Lexaria Corp CSE:LXX OTC:LXRP
Thanks for the links everyone and yes Webinar was excellent. Here is the last news I do not see posted here
2017-11-02 09:03 ET - News Release
Mr. Chris Bunka reports
LEXARIA BIOSCIENCE ACQUIRES 100% OWNERSHIP OF POVIVA TEA LLC
Lexaria Bioscience Corp. has acquired 100-per-cent ownership interest in its majority-owned subsidiary Poviva Tea LLC.
Lexaria previously owned a 51-per-cent interest in Poviva Tea LLC and has acquired the remaining 49-per-cent interest. The acquisition consolidates ownership of Poviva Tea LLC as a wholly owned Lexaria Bioscience subsidiary and simplifies future operations and certain intellectual property ownership. Compensation was $70,000 (U.S.), a waiver on certain debts, and a 5-per-cent, 20-year royalty on net profits of ViPova Tea tea, coffee and hot chocolate sales. No Lexaria stock or options were issued.
"This acquisition strengthens Lexaria's intellectual property positioning and we reaffirm our commitment to the ViPova Tea product lines," said chief executive officer Chris Bunka. "Lexaria thanks the founders of Poviva Tea LLC for their assistance and vision in this transaction."
Lexaria's patented DehydraTech technology is focused on improved delivery methodologies of many commonly used active pharmaceutical ingredients (APIs) substances. As such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of third parties. Both patented and generic API substances can utilize Lexaria's patented technology. Lexaria's long-term strategy is to partner with the world's leading firms as they deliver best-of-class products to their existing large consumer groups.
About Lexaria Bioscience Corp.
Lexaria has developed and outlicenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patents in the United States and in Australia related to edible forms of cannabinoids.